You just read:

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

News provided by

EpicentRx

Jun 25, 2019, 06:00 ET